Jefferies raises PT on Australia's Telix Pharma after deal with ITM Isotope Technologies

** Jefferies upgrades price target on Telix Pharmaceuticals TLX.AX to A$32 from A$30

** Last week, co said it will acquire Germany-based ITM Isotope Technologies for an upfront consideration of $1.65 billion

** Brokerage ups TLX's FY27 EBITDA estimate by 10% and FY28 EBITDA estimate by 30%

** 12 of 13 analysts rate the stock "buy" or higher, 1 "hold"; their median PT is A$22, according to data compiled by LSEG

** Stock up 40.4% YTD as of last close